ArticleArthritis research & therapy2026
Frailty as an indicator of adverse health outcomes in rheumatoid arthritis: a multicenter cross-sectional study.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundFrailty has emerged as a common and clinically relevant condition in rheumatoid arthritis (RA). However, comprehensive evidence linking frailty with both physical and mental health outcomes in RA remains limited, particularly in low- and middle-income settings. This study aimed to explore the association between frailty and adverse health outcomes in participants with RA, focusing on disease activity, physical function, anxiety, depression, and health-related quality of life (HRQoL).
methodsA multicenter cross-sectional study was conducted in Tianjin, China, from November 2023 to August 2024. Frailty was assessed using the FRAIL scale, with multiple linear regression models applied to examine the associations between frailty status and the specified health outcomes. Frailty and pre-frailty were treated as independent variables in all models. Covariates included demographic, lifestyle, and clinical factors, and full adjustment was performed in the final model.
resultsA total of 823 participants with RA were enrolled. After full adjustment, frailty was significantly associated with higher disease activity, poorer physical function, elevated anxiety and depression, and lower HRQoL (all P < 0.001). Pre-frailty was also significantly associated with higher disease activity, worse physical function, greater depression, and lower HRQoL (all P < 0.001) but not with anxiety (P = 0.786).
conclusionsFrailty is a significant indicator of adverse health outcomes in RA, and even pre-frailty signals a higher vulnerability to poor health outcomes. Incorporating frailty assessment into routine RA management and identifying individuals at the pre-frail stage may provide critical opportunities for early intervention and improved long-term outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.